Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Notes underwriting agrmnt
Inv. presentation
Quarterly results
Appointed COO
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update"
07/19/2023 8-K Quarterly results
07/19/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update"
04/05/2023 SC 13G/A Ness Kevin Dean reports a 10% stake in Brainstorm Cell Therapeutics Inc.
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
03/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS"
01/11/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
01/04/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "AMENDMENT No. 3 TO OFFER LETTER AGREEMENT",
"SEPARATION AGREEMENT",
"BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer"
12/13/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update"
09/22/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "AMENDMENT No. 2 TO OFFER LETTER AGREEMENT"
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/16/2022 8-K Quarterly results
03/28/2022 10-K Annual Report for the period ended December 31, 2021
03/28/2022 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update"
02/14/2022 SC 13G Abbhi Investments, LLC reports a 6.7% stake in Brainstorm Cell Therapeutics Inc.
02/04/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/28/2022 8-K Quarterly results
Docs: "BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update",
"Transcript of Conference Call by the Company on November 15, 2021, furnished hereto"
12/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/10/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/15/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/04/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/29/2021 8-K Appointed a new director
Docs: "Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors"
08/25/2021 8-K Quarterly results
08/13/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
08/09/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy